This test can be performed using the following sample types: Blood, Buccal Swab, or Saliva. Please contact us for detailed sample collection guidance.
OMI® PGx Pharmacogenomics NGS Testing
Precision Medicine for Safer, More Effective Treatment
International Shipping Available
OMI® PGx
Treatment Based On Your Unique Genetic Code
OMI® PGx Pharmacogenomics NGS Testing analyzes key genetic variants involved in drug metabolism, transport, and therapeutic response to help healthcare providers make more informed prescribing decisions.
Using advanced Next-Generation Sequencing (NGS) technology and internationally recognized pharmacogenetic guidelines, this analysis provides personalized insights into how an individual's genetics may influence medication effectiveness and safety.
30%
Why Pharmacogenomics?
30% of patients experience Adverse Drug Reactions that could be prevented with PGx testing
PREPARE Randomized Clinical Trial (2023). The Lancet.
Potential Benefits
Identify medications that may be less effective
Reduce the risk of adverse drug reactions
Support safer medication selection
Guide dose optimization
Reduce trial-and-error prescribing
Who May Benefit?
This assessment may be considered for individuals experiencing:
Have experienced medication side effects
Require multiple prescription medications
Have had limited success with previous treatments
Are beginning long-term medication therapy
Have a history of unusual drug responses
Are seeking a more personalized approach to treatment
Cardiovascular Medicine
Endocrine Disorders
Hypertension
Respiratory Medicine
Diabetes
Neurology & Psychiatry
Infections
Urogenital Conditions
Digestive System Disorders
Oncology Supportive Care
Gout
Autoimmune Disorders
Musculoskeletal Conditions
Commonly Prescribed Medicines
What Is Tested?
OMI ® PGx NGS Testing evaluates clinically relevant pharmacogenes involved in drug metabolism, transport, and therapeutic response.
Drug-Metabolizing Enzymes
Drug Transporters
Drug Targets & Receptors
Advanced Genomic Technology
OMI® PGx utilizes high-depth Next-Generation Sequencing technology to ensure accurate and reliable variant detection
Analytical Features
High-confidence sequencing depth (≥300×)
Comprehensive pharmacogene coverage
Automated variant annotation using established clinical databases
Phenotype prediction models identifying metabolizer status
Continuous interpretation updates aligned with evolving scientific evidence
What This Means for Patients
Personalized Medication Guidance
Patients may be classified into categories such as:
Actionable Clinical Report
The final report integrates genetic findings with internationally recognized pharmacogenetic recommendations to provide practical guidance for healthcare providers.
Identified pharmacogenetic variants
Predicted metabolizer status
Medication-specific gene interactions
Potential efficacy considerations
Adverse reaction risk assessments
Dosing considerations where applicable
Evidence-based therapeutic recommendations
Results You Can Trust
Interpretations are based on guidance from reputable sources.
Interpretation protocols are continuously reviewed and updated to reflect the latest pharmacogenetic evidence and CPIC guideline revisions.
Sample Information
TAT
Results should be expected approximately 30 days from the date the sample reaches our lab partners.
International Availability
International shipping for this test is available. Please consult our team for information regarding your specific country.
Contact Us
References
- Pirmohamed M et al. "Preemptive pharmacogenomic testing for preventing adverse drug reactions: the PREPARE randomized clinical trial." The Lancet. 2023.
Results from OMI ® PGx Pharmacogenomic NGS Testing are not intended to be used as independent medical advice. The analysis should be contextualized within the patient’s broader clinical context, and final treatment decisions are up to the patient and their treating physician. Always consult your physician regarding your medication plans.
Founded by Parents.
Supported by Experts.
Trusted by Families Worldwide.
© 2026 NeurAnova. All rights reserved.